

# The direct effects of non-steroidal anti-inflammatory drugs (NSAIDs) on osteoarthritic knee cartilage

<b>Submission date</b> 20/12/2005	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
<b>Registration date</b> 20/12/2005	<b>Overall study status</b> Completed	<input type="checkbox"/> Protocol
<b>Last Edited</b> 15/05/2009	<b>Condition category</b> Musculoskeletal Diseases	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

## Plain English summary of protocol

Not provided at time of registration

## Contact information

### Type(s)

Scientific

### Contact name

Dr A C A Marijnissen

### Contact details

UMC Utrecht  
Rheumatology & Clin. Immunology, F02.127  
P.O. Box 85500  
Utrecht  
Netherlands  
3508 GA  
+31 (0)30 250 9758  
[a.c.a.marijnissen@umcutrecht.nl](mailto:a.c.a.marijnissen@umcutrecht.nl)

## Additional identifiers

### Protocol serial number

NTR159

## Study information

Scientific Title

Selective COX-2 inhibition is beneficial for matrix turnover: a clinical study

### **Study objectives**

Selective COX-2 inhibition is beneficial for matrix turnover.

### **Ethics approval required**

Old ethics approval format

### **Ethics approval(s)**

Received from the local medical ethics committee

### **Study design**

Randomised active controlled parallel group trial

### **Primary study design**

Interventional

### **Study type(s)**

Treatment

### **Health condition(s) or problem(s) studied**

Osteoarthritis

### **Interventions**

Celecoxib: 4 weeks, 2 times per day, 200 mg

Naproxen: 4 weeks, 3 times per day, 250 mg

Indomethacin: 4 weeks, 2 times per day, 50 mg

### **Intervention Type**

Drug

### **Phase**

Not Applicable

### **Drug/device/biological/vaccine name(s)**

Celecoxib, naproxen, indomethacin

### **Primary outcome(s)**

Difference in proteoglycan release of osteoarthritic cartilage after treatment

### **Key secondary outcome(s)**

Proteoglycan E2 levels produced by cartilage

### **Completion date**

01/12/2005

## **Eligibility**

### **Key inclusion criteria**

Patients with knee osteoarthritis according to the American College of Rheumatology (ACR) criteria, considered for total knee replacement surgery.

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Not Specified

**Sex**

Not Specified

**Key exclusion criteria**

1. Total knee replacement for other reason than osteoarthritis
2. History of gastro-intestinal bleedings or perforation
3. Increased risk for cardiovascular diseases (cardiovascular diseases in history, patients with untreated hypertension, patients with angina pectoris, and patients on oral anticoagulants)

**Date of first enrolment**

01/11/2004

**Date of final enrolment**

01/12/2005

**Locations****Countries of recruitment**

Netherlands

**Study participating centre**

UMC Utrecht

Utrecht

Netherlands

3508 GA

**Sponsor information****Organisation**

University Medical Centre Utrecht (UMCU) (Netherlands)

ROR

<https://ror.org/04pp8hn57>

## **Funder(s)**

### **Funder type**

Not defined

### **Funder Name**

Not provided at time of registration

## **Results and Publications**

### **Individual participant data (IPD) sharing plan**

### **IPD sharing plan summary**

Not provided at time of registration